Repligen (NASDAQ:RGEN) Given Outperform Rating at Wolfe Research

Repligen (NASDAQ:RGEN)‘s stock had its “outperform” rating reaffirmed by research analysts at Wolfe Research in a report issued on Tuesday,Benzinga reports. They presently have a $145.00 target price on the biotechnology company’s stock. Wolfe Research’s price target would suggest a potential upside of 17.79% from the company’s current price.

Several other analysts also recently commented on RGEN. Rothschild & Co Redburn set a $160.00 target price on shares of Repligen and gave the company a “buy” rating in a report on Friday, April 17th. Canaccord Genuity Group lowered their target price on shares of Repligen from $165.00 to $145.00 and set a “hold” rating for the company in a report on Monday, April 20th. JPMorgan Chase & Co. lowered their target price on shares of Repligen from $180.00 to $165.00 and set an “overweight” rating for the company in a report on Wednesday, May 6th. Barclays increased their target price on shares of Repligen from $145.00 to $160.00 and gave the company an “overweight” rating in a report on Wednesday, May 6th. Finally, KeyCorp reiterated an “overweight” rating on shares of Repligen in a report on Wednesday, February 25th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Repligen presently has an average rating of “Moderate Buy” and a consensus price target of $164.64.

Repligen Price Performance

NASDAQ:RGEN opened at $123.10 on Tuesday. Repligen has a 52 week low of $100.99 and a 52 week high of $175.77. The firm has a market cap of $6.94 billion, a price-to-earnings ratio of 136.78, a P/E/G ratio of 2.39 and a beta of 1.09. The firm’s 50-day simple moving average is $118.05 and its 200 day simple moving average is $139.53. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.78 and a current ratio of 9.20.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.38 by $0.10. Repligen had a net margin of 6.73% and a return on equity of 4.88%. The company had revenue of $194.26 million for the quarter, compared to analyst estimates of $192.05 million. During the same period in the previous year, the firm posted $0.39 EPS. The firm’s revenue was up 14.8% on a year-over-year basis. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. As a group, sell-side analysts predict that Repligen will post 1.99 earnings per share for the current year.

Institutional Trading of Repligen

A number of institutional investors and hedge funds have recently made changes to their positions in RGEN. Price T Rowe Associates Inc. MD lifted its stake in shares of Repligen by 31.1% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,599,061 shares of the biotechnology company’s stock valued at $753,603,000 after purchasing an additional 1,091,683 shares during the last quarter. United Capital Financial Advisors LLC bought a new position in shares of Repligen during the third quarter valued at approximately $368,387,000. Opti Capital Management LP acquired a new position in shares of Repligen during the fourth quarter worth approximately $2,399,209,000. Maverick Capital Ltd. acquired a new position in shares of Repligen during the first quarter worth approximately $178,946,000. Finally, Holocene Advisors LP boosted its position in shares of Repligen by 47.0% during the third quarter. Holocene Advisors LP now owns 1,377,104 shares of the biotechnology company’s stock worth $184,077,000 after buying an additional 440,290 shares during the period. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.